BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35606470)

  • 1. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.
    Tsujimae M; Masuda A; Ikegawa T; Tanaka T; Inoue J; Toyama H; Sofue K; Uemura H; Kohashi S; Inomata N; Nagao K; Masuda S; Abe S; Gonda M; Yamakawa K; Ashina S; Yamada Y; Tanaka S; Nakano R; Sakai A; Kobayashi T; Shiomi H; Kanzawa M; Itoh T; Fukumoto T; Ueda Y; Kodama Y
    Ann Surg Oncol; 2022 Aug; 29(8):4924-4934. PubMed ID: 35606470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
    Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
    Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.
    Matsuda R; Miyasaka Y; Ohishi Y; Yamamoto T; Saeki K; Mochidome N; Abe A; Ozono K; Shindo K; Ohtsuka T; Kikutake C; Nakamura M; Oda Y
    Ann Surg; 2020 May; 271(5):941-948. PubMed ID: 30308608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm.
    Yagi Y; Masuda A; Zen Y; Shiomi H; Toyama H; Sofue K; Takenaka M; Kobayashi T; Nakagawa T; Yamanaka K; Ikegawa T; Hoshi N; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Ku Y; Azuma T
    Pancreatology; 2018 Jan; 18(1):54-60. PubMed ID: 29269290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.
    Yamada S; Fujii T; Hirakawa A; Takami H; Suenaga M; Hayashi M; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Pancreas; 2018 Sep; 47(8):974-979. PubMed ID: 30028445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
    Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
    Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm.
    Nakagawa T; Masuda A; Toyama H; Shiomi H; Zen Y; Sofue K; Takenaka M; Kobayashi T; Yagi Y; Yamanaka K; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Ku Y; Azuma T
    Pancreas; 2017 Apr; 46(4):582-588. PubMed ID: 28099253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
    Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
    Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm.
    Ikegawa T; Masuda A; Sakai A; Toyama H; Zen Y; Sofue K; Nakagawa T; Shiomi H; Takenaka M; Kobayashi T; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Azuma T
    Pancreatology; 2018 Jun; 18(4):399-406. PubMed ID: 29685673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.